Did Kestra Medical beat or miss consensus estimates last quarter?

What is Kestra Medical's latest dividend and current dividend yield?

What is the market's earnings forecast for Kestra Medical next quarter?

What were the key takeaways from Kestra Medical's earnings call?

What is Kestra Medical's gross profit margin?

What does Kestra Medical do and what are its main business segments?

What guidance did Kestra Medical's management provide for the next earnings period?

What factors drove the changes in Kestra Medical's revenue and profit?

- **Revenue Growth Accelerates**: Q1 2026 revenue up 52% YoY to $19.4M, driven by 51% prescription growth. 
- **Gross Margin Expansion**: 45.7% (vs. 32.9% prior year), on track for 70%+ in a few years. 
- **Clinical Validation**: Late-breaking AHA study to present 25,000-patient data, solidifying compliance and safety leadership. 
- **Market Opportunity**: 6x underserved patients in $1B+ WCD market. 
- **Operational Efficiency**: 80% in-network mix, 47% conversion rate, and $201M cash runway.

**【CEO Summary Section】**
- Q1 2026 revenue reached $19.4 million, up 52% YoY, driven by 51% YoY increase in prescriptions (4,200+ ASSURE system prescriptions). 
- Gross margin expanded to 45.7% (vs. 32.9% prior year), with 7 consecutive quarters of margin improvement. 
- Key growth drivers: 
  1. Sales expansion (80+ territories, targeting high-WCD geographies) 
  2. RCM improvements (in-network mix 80% vs. 70% at IPO) 
  3. Fleet scale (3 patient wears/device/year) 
  4. Clinical evidence (FDA post-approval study enrollment complete)
- WCD market penetration at ~14%, with 6x underserved patients. Late-breaking AHA study will present 25,000-patient data on compliance, safety, and outcomes.

**【CFO Financial Commentary】**
- Q1 GAAP net loss: $25.8M (vs. $20.3M prior year). Adjusted EBITDA loss: $19.4M (vs. $15.7M). 
- FY26 revenue guidance raised to $88M (47% YoY growth). 
- Conversion rate 47% (vs. 40% prior year), driven by: 
  - 20% cost per fit decline 
  - 20% revenue per fit increase 
  - 80% in-network mix (vs. 70% at IPO)
- Cash reserves: $201.2M, with $15M available under term loan. 
- Targeting 70%+ gross margins through scale and volume leverage.

**【Q&A Highlights】**
- **Prescription Growth**: Sequential +300 prescriptions, annualizing to ~14% market share. 
- **In-Network Strategy**: Focused on 3,000+ payers, prioritizing high-WCD geographies. 
- **Compliance**: Median daily wear >23 hours, sustained adherence >90 days. 
- **Competitive Position**: Incumbent competitor's SCD PROTECT study validates WCD need, but Kestra offers superior compliance and outcomes. 
- **OpEx Cadence**: Steady territory expansion with ~50% U.S. coverage, targeting 100% over time.

KMTS

KMTS fundamentals

You can ask Aime